MAIA Biotechnology

Historical price data

MAIA Biotechnology is a targeted therapy and immuno-oncology company focused on developing first-in-class drugs with novel mechanisms of action to improve and extend the lives of cancer patients. Its core achievement is the advancement of its lead asset, ateganosine (THIO), a dual-mechanism telomere-targeting agent, into Phase 2 clinical trials. The company's strategy leverages a proprietary platform of telomere biology to induce direct cancer cell death and generate an immunogenic response, differentiating it from conventional therapies. MAIA operates as a public entity, trading on the NYSE American exchange, and is positioned within the high-potential RNA & Gene Therapy sector.

A proprietary telomere-targeting immuno-oncology platform that develops small molecules designed to be incorporated into cancer cell telomeres, disrupting their structure to induce direct cell death and stimulate an anti-tumor immune response.

Direct competition in clinical-stage, small-molecule telomere-targeting is limited, but MAIA faces indirect competition from the entire field of oncology therapeutics, including established immunotherapies and novel modalities. Its primary advantage is the novelty of its dual-mechanism platform targeting a fundamental cancer hallmark.